Infrared low-level laser therapy enhances proliferation and viability in murine osteoblasts in vitro

体外实验表明,低强度红外激光疗法可增强小鼠成骨细胞的增殖和存活率。

阅读:1

Abstract

PURPOSE: Infrared low-level laser therapy (LLLT) has shown great promise in promoting cell proliferation and viability, making it a valuable tool in regenerative medicine. This study investigated how the interval between sessions shapes the response to 970 nm LLLT in murine osteoblast cultures by delivering three 10 J/cm² sessions separated by 24-48 h and measuring proliferation, reactive oxygen species (ROS), cytotoxicity, and apoptosis, with the goal of informing protocol design for bone regeneration. METHODS: Two osteoblast cultures were used, one control and the other LLL-treated group. The latter consisted of three irradiation sessions (10 J/cm(2) each) applied at 24, 48, and 96 h. RESULTS: The experimental results showed a significant increase in cell proliferation after two and three sessions (p < 0.05), while ROS levels progressively accumulated, peaking after the third session (p < 0.001). Cell viability remained above 90% in both groups during the first 48 h; however, a slight but significant reduction was observed in the LLLT group at 96 h. Apoptosis levels were lower in LLLT-treated cells during early phases (24-48 h), suggesting a transient cytoprotective effect that diminished after the third session. These findings indicate that infrared LLLT promotes cell proliferation without inducing cytotoxicity or programmed cell death. CONCLUSION: The results demonstrate that applying three infrared LLLT sessions of 10 J/cm² applied at 24, 48, and 96 h promotes osteoblastic proliferation and viability without inducing cytotoxicity or apoptosis. The proposed protocol, defined by energy dose and irradiation timing, provides a safe and effective strategy for bone tissue engineering.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。